BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types
SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today is hosting a virtual R&D Day on its novel conditionally and reversibly active antibody targeting CTLA-4, BA3071. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent.
- BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent.
- The event will feature Omid Hamid, MD, Chief, Translational Research and Immunotherapy, and Director, Melanoma Therapeutics at The Angeles Clinic and Research Institute, and highlights Phase 1 dose escalation trial results for BA3071.
- In addition, the relatively low incidence of immune-related adverse events suggests our CAB antibody has the potential to address the current limitations of CTLA-4-targeted therapies."
- Exposure levels of BA3071 were similar to that of ipilimumab analog, with significantly less GI toxicity when combined with nivolumab in a non-human primate model.